A drugs company has announced that development of a new inhaler product has moved a step closer following notification from the European Medicines Agency (EMEA).
The inhaled apomorphine product is designed to ease the discomfort of sufferers of Parkinson's disease during "off episodes" and claims to reduce the impact of side effects associated with other similar treatments.
Found in advanced stage patients, the off episodes significantly reduce the person's abilities to carry out normal tasks and take the form of lack of co-ordination, muscle cramp and cognitive slowing.
Apomorphine is usually administered subcutaneously but the new Vectura VR040 product will allow for a non-invasive option and enable some self-administration, as well as lowering side effects.
"We are delighted that we can now pursue a rapid development programme and utilise advice from the EMEA to make our inhaled apomorphine product available to patients as quickly as possible," commented Vectura's chief executive, Dr Chris Blackwell.
Clinical development will begin this year and it is a sign that future treatments may help to improve quality of life for people with Parkinson's disease.